


Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

Jörg T Regula, Peter Lundh von Leithner, Richard Foxton, Veluchamy A Barathi, Chui Ming Gemmy Cheung, Sai Bo Bo Tun, Yeo Sia Wey, Daiju Iwata, Miroslav Dostalek, Jörg Moelleken, Kay G Stubenrauch, Everson Nogoceke, Gabriella Widmer, Pamela Strassburger, Michael J Koss, Christian Klein, David T Shima & Guido Hartmann 

Correction to: *EMBO Mol Med* (2016) 8: 1265–1288. DOI 10.15252/emmm.201505889 | Published online 14 October 2016

This editorial expression of concern is to alert our readership that the data presented in Figures 4 and 5 require further analysis and verification. The scientific record will be updated once this process has been completed.

J.T.R., P.L.v.L., R.F., D.I., E.N., G.W., P.S., C.K., D.T.S., and G.H. agree. The other authors could either not be reached or did not provide a response.